Varicella–Zoster Vaccine for the Prevention of Herpes Zoster
- 29 March 2007
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (13) , 1338-1343
- https://doi.org/10.1056/nejmct066061
Abstract
A 64-year-old man in good general health presents to his internist for a routine examination. In a large clinical trial, the varicella–zoster vaccine reduced the incidence of herpes zoster by 51% and the incidence of postherpetic neuralgia by 67%. Should he receive this vaccine?Keywords
This publication has 33 references indexed in Scilit:
- The burden of Herpes Zoster: A prospective population based studyVaccine, 2006
- Aging, Immunity, and the Varicella–Zoster VirusNew England Journal of Medicine, 2005
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- A study of shingles and the development of postherpetic neuralgia in East LondonJournal of Medical Virology, 2003
- Treatment of Postherpetic NeuralgiaDrugs, 2000
- The sequelae of herpes zosterArchives of internal medicine (1960), 1997
- Postherpetic Neuralgia — Pathogenesis, Treatment, and PreventionNew England Journal of Medicine, 1996
- Herpes Zoster and Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1992
- Varicella and Herpes ZosterNew England Journal of Medicine, 1983
- Herpes ZosterSouthern Medical Journal, 1976